Mon, Apr 14, 8:06 PM (12 days ago)
### Summary of GT Biopharma, Inc. (GTBP) 10-K/A Amendment **Company Overview:** GT Biopharma, Inc. (GTBP) filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The amendment primarily updates the Exhibit Index to include the Company’s Compensation Recovery Policy as Exhibit 97.1. **Financial Performance:** The amendment does not include any new financial statements or updates to previously reported financial information. Therefore, the financial performance, revenue, net income, operating expenses, and earnings per share remain as reported in the Original 2024 10-K. **Strategic Overview:** GT Biopharma became a fully remote company effective July 1, 2024, eliminating the need for a principal executive office. This strategic shift aligns with operational efficiencies and cost management. **Future Outlook:** The amendment does not provide new insights into the future outlook. Investors should refer to the Original 2024 10-K for strategic initiatives and future projections. **Risk Factors:** No new risk factors were disclosed in this amendment. Existing risk factors remain as previously reported. **Financial Condition:** The financial condition of the company remains unchanged from the Original 2024 10-K. The aggregate market value of the common stock held by non-affiliates was approximately $5.1 million as of June 30, 2024, with 2,234,328 shares issued and outstanding as of February 19, 2025. **Market Position Changes:** No significant changes in market position were reported in this amendment. The company continues to operate in the biopharma sector, focusing on its core competencies. **Conclusion:** This amendment is primarily administrative, updating the Exhibit Index to include the Compensation Recovery Policy. For detailed financial and operational insights, portfolio managers, traders, and finance professionals should refer to the Original 2024 10-K and other filings with the SEC.